Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BGB-DXP604 Alone and with BGB-DXP593 in Healthy Subjects
NCT04669262Phase 1Completed
- Sponsor
- BeiGene
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DXP-604 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by BeiGene. Primary endpoint: Treatment Emergent Adverse Events. Started Dec 2020; status: completed.
02
Drugs
DXP-604
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04669262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669262.